Candel Therapeutics (CADL) Competitors $4.85 +0.06 (+1.25%) Closing price 04:00 PM EasternExtended Trading$4.90 +0.05 (+1.03%) As of 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CADL vs. UPB, SION, ORIC, PHAR, SYRE, SPRY, PRAX, QURE, ATAI, and CRONShould you be buying Candel Therapeutics stock or one of its competitors? The main competitors of Candel Therapeutics include Upstream Bio (UPB), Sionna Therapeutics (SION), Oric Pharmaceuticals (ORIC), Pharming Group (PHAR), Spyre Therapeutics (SYRE), ARS Pharmaceuticals (SPRY), Praxis Precision Medicines (PRAX), uniQure (QURE), atai Life Sciences (ATAI), and Cronos Group (CRON). These companies are all part of the "pharmaceutical products" industry. Candel Therapeutics vs. Its Competitors Upstream Bio Sionna Therapeutics Oric Pharmaceuticals Pharming Group Spyre Therapeutics ARS Pharmaceuticals Praxis Precision Medicines uniQure atai Life Sciences Cronos Group Upstream Bio (NASDAQ:UPB) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends. Do analysts recommend UPB or CADL? Upstream Bio currently has a consensus price target of $56.50, indicating a potential upside of 236.51%. Candel Therapeutics has a consensus price target of $20.00, indicating a potential upside of 312.37%. Given Candel Therapeutics' higher probable upside, analysts plainly believe Candel Therapeutics is more favorable than Upstream Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Upstream Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Candel Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in UPB or CADL? 13.9% of Candel Therapeutics shares are owned by institutional investors. 13.6% of Upstream Bio shares are owned by insiders. Comparatively, 16.6% of Candel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media prefer UPB or CADL? In the previous week, Upstream Bio had 3 more articles in the media than Candel Therapeutics. MarketBeat recorded 5 mentions for Upstream Bio and 2 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of 1.22 beat Upstream Bio's score of 1.15 indicating that Candel Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Upstream Bio 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Candel Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation and earnings, UPB or CADL? Candel Therapeutics has lower revenue, but higher earnings than Upstream Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUpstream Bio$2.72M332.40-$62.81MN/AN/ACandel Therapeutics$120K2,218.88-$55.18M-$0.69-7.03 Is UPB or CADL more profitable? Candel Therapeutics has a net margin of 0.00% compared to Upstream Bio's net margin of -3,836.58%. Upstream Bio's return on equity of -35.90% beat Candel Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Upstream Bio-3,836.58% -35.90% -26.26% Candel Therapeutics N/A -41.00%-26.81% SummaryCandel Therapeutics beats Upstream Bio on 8 of the 13 factors compared between the two stocks. Get Candel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CADL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CADL vs. The Competition Export to ExcelMetricCandel TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$266.27M$3.10B$5.75B$10.27BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-7.0321.3874.9226.41Price / Sales2,218.88243.79457.0188.61Price / CashN/A44.4425.8129.91Price / Book3.449.6413.256.28Net Income-$55.18M-$53.20M$3.29B$270.38M7 Day Performance-4.90%0.44%0.47%2.70%1 Month Performance-20.36%4.26%4.59%5.99%1 Year Performance-30.81%9.43%73.41%25.94% Candel Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CADLCandel Therapeutics2.3851 of 5 stars$4.85+1.3%$20.00+312.4%-31.7%$266.27M$120K-7.0360UPBUpstream Bio1.8364 of 5 stars$18.73-6.2%$56.50+201.7%N/A$1.08B$2.37M0.0038Positive NewsSIONSionna Therapeutics2.8247 of 5 stars$21.62-9.9%$38.00+75.8%N/A$1.06BN/A0.0035High Trading VolumeORICOric Pharmaceuticals4.5524 of 5 stars$10.50-3.5%$17.29+64.6%+9.0%$1.06BN/A-5.5680Positive NewsPHARPharming Group2.2219 of 5 stars$14.80-3.0%$30.00+102.7%+95.7%$1.05B$297.20M-113.85280News CoverageShort Interest ↑SYRESpyre Therapeutics2.2676 of 5 stars$16.63-2.2%$53.40+221.1%-46.7%$1.03B$890K-4.8973News CoveragePositive NewsSPRYARS Pharmaceuticals2.6058 of 5 stars$10.70+6.3%$32.50+203.7%-24.6%$995.18M$89.15M-21.8490PRAXPraxis Precision Medicines2.4634 of 5 stars$40.75-13.0%$85.88+110.7%-37.0%$985.99M$8.55M-3.32110Positive NewsHigh Trading VolumeQUREuniQure3.2192 of 5 stars$17.43-2.9%$37.45+114.9%+191.3%$984.86M$27.12M-4.45500ATAIatai Life Sciences2.8938 of 5 stars$4.52-1.1%$11.25+148.9%+256.2%$979.53M$310K-6.5580Positive NewsCRONCronos Group2.4842 of 5 stars$2.48-0.8%N/A+16.1%$957.23M$117.61M49.60450 Related Companies and Tools Related Companies UPB Competitors SION Competitors ORIC Competitors PHAR Competitors SYRE Competitors SPRY Competitors PRAX Competitors QURE Competitors ATAI Competitors CRON Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CADL) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Candel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Candel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CADL Stock Alerts